Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06676579 · ClinicalTrials.gov registry record · Phase 2
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
A Phase 2 study of IgA Nephropathy (IgAN), sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT06676579 is a Phase 2 study of IgA Nephropathy (IgAN) that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 16 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06676579, a Phase 2 study of IgA Nephropathy (IgAN), is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Prednisolone
- DRUG Avacopan
- DRUG Methylprednisolone (drug)
Study Locations (2)
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2029-03-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06676579
The ClinicalTrials.gov registry entry for NCT06676579 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with IgA Nephropathy (IgAN) appearing as the primary indexed condition, and to 4 interventions - of which Prednisone is the first listed.
NCT06676579 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06676579 about?
NCT06676579 is a clinical study titled "Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)". The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.
What is the current status of trial NCT06676579?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2025-06-09. Estimated completion is 2029-03-02.
What conditions does trial NCT06676579 study?
This clinical trial studies the following conditions: IgA Nephropathy (IgAN).
What interventions are being tested in trial NCT06676579?
The interventions under investigation include: Prednisone (DRUG), Prednisolone (DRUG), Avacopan (DRUG), Methylprednisolone (drug) (DRUG).
Who is sponsoring clinical trial NCT06676579?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06676579 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgA Nephropathy (IgAN)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.